SFM
ZNTL icon

Signet Financial Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Signet Financial Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-235
Closed -$20K – 1381
2021
Q4 		$20K Buy
+235
New +$18.2K ﹤0.01% 884

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Signet Financial Management's ZNTL Position: Q1 2022 in Review

Signet Financial Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2022, closing a stake of 235 shares — an estimated $20K sold.

Signet Financial Management first reported a position in ZNTL in Q4 2021 and held it in 1 quarter. The position peaked at $20K in Q4 2021. 128 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

  • Signet Financial Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 235 Zentalis Pharmaceuticals shares in Q1 2022, an estimated $20K.
  • Signet Financial Management first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's Zentalis Pharmaceuticals position peaked at $20K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.